Co-Amoxiclav

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Amoxiclav

Quick Facts

Property Description
Active Ingredients Amoxicillin, Clavulanic Acid
Form Tablet, Oral Suspension, Powder for Injection
Pharmacological Class Broad-spectrum Antibiotic (Penicillin)
Origin Semisynthetic and Synthetic Combination
General Purpose Resolution of Bacterial Infections

What Type of Medicine is Co-Amoxiclav?

Co-Amoxiclav is the internationally recognized name for the combination of Amoxicillin and Clavulanic Acid, which functions as a prescription-only, fixed-dose combination drug. It is classified as an Antibacterial agent in the Penicillin group. This medicine is a systemic preparation intended for internal use, delivered as a tablet, an oral suspension, or a powder for injection. The formulation involves two active components: Amoxicillin, a semisynthetic penicillin derivative, and Clavulanic Acid, which is the synthetic protective component. This combination is widely known under major trade names such as Augmentin and Clavulin, demonstrating its clinically recognized position in treating a variety of infections.

Why are Amoxicillin and Clavulanic Acid Combined?

The two ingredients are strategically combined to achieve a potent synergistic action, thereby expanding the drug's overall therapeutic spectrum and protecting its core function. The rationale for Co-Amoxiclav is rooted in the fact that many bacteria produce destructive enzymes called beta-lactamases, which can inactivate Amoxicillin. Clavulanic Acid functions by irreversibly binding to these enzymes, effectively shielding the antibiotic. This protection ensures that the Amoxicillin component can successfully disrupt bacterial cell wall synthesis, maintaining its potent bactericidal effect and enabling the drug to effectively clear a wide range of bacterial infections, particularly those caused by resistant strains. The efficacy of this combination against resistance mechanisms is a key feature of its pharmacological profile.

Regulatory References

  1. European Medicines Agency (EMA)
  2. supported by pharmacological studies

What side effects are possible with Co-Amoxiclav ?

Possible Side Effects and Safety Information

The safety profile of Co-Amoxiclav (Amoxicillin and Clavulanic Acid) is officially documented by government regulatory bodies, classifying potential effects by frequency and the body system affected. These classifications establish the known risk profile of the medicine.

Frequency and System Classification

Adverse reactions are formally categorized based on official reporting rates. The most frequently documented reactions involve the gastrointestinal system and skin. Diarrhoea is classified as Very Common in adults (occurring in 1/10 patients). Other Common effects (occurring in 1/100 to < 1/10) include mucocutaneous candidosis (thrush), nausea, and vomiting. Reactions such as skin rash, headache, and dizziness are classified as Uncommon.

Serious Adverse Reactions

Regulatory information highlights specific events that, while often rare, represent serious risks. These include Severe Allergic Reactions, such as anaphylaxis and angioneurotic oedema, and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Hepatic dysfunction and cholestatic jaundice are also documented as serious risks, with signs sometimes appearing several weeks after treatment has ceased. The risk of antibiotic-associated colitis and convulsions is also noted.

Population-Specific Safety Notes

The official label includes specific considerations for certain patient groups. Hepatic events have been reported predominantly in older patients and may be associated with prolonged treatment. Convulsions are noted to potentially occur in patients with impaired renal function. The medication is formally restricted for use in patients with a prior history of hepatic dysfunction or cholestatic jaundice specifically linked to this combination.

Overdose and Emergency Response

Overdose and When to Seek Help

Suspected overdose with Co-Amoxiclav requires immediate medical attention. Regulatory authorities uniformly mandate that individuals must contact a poison control center or emergency services right away.

Overexposure may initially present with gastrointestinal symptoms such as vomiting, diarrhea, and abdominal pain. Documented central nervous system effects include drowsiness, excitement, and hyperactivity.


Severe Outcomes and Required Monitoring

Overdose carries documented risks of serious systemic complications. These severe outcomes include the potential for convulsions (seizures), acute renal failure, and impairment of fluid and electrolyte balance.

Specifically, the Amoxicillin component may lead to crystalluria, a factor documented to contribute to renal injury, particularly in patients with reduced urine output. Therefore, clinical observation requires continuous monitoring of fluid and electrolyte balance and renal status.

Management and Emergency Action

As no specific antidote is known, management is officially defined as symptomatic and supportive treatment. Supportive procedures described in official labeling may include haemodialysis, as the active ingredients are dialyzable, and measures like gastric lavage or activated charcoal to limit absorption. These steps are exclusively applied in a monitored healthcare setting.

Therapeutic Uses of Co-Amoxiclav

What Co-Amoxiclav Treats: Main Uses and Benefits

Co-Amoxiclav is commonly used to help with a broad range of bacterial infections across different parts of the body in adults and children. The therapeutic role of Co-Amoxiclav is widely understood across major infectious disease domains.

This medication is relevant for conditions presenting with acute or disruptive symptom patterns, including infections of the respiratory tract (like pneumonia and sinusitis), urinary tract, skin and soft tissues (such as cellulitis), and dental abscesses. It is strategically employed for more challenging infections, particularly when a resistant bacterial strain is suspected.

Its primary role is to provide a supportive therapeutic option that may assist in easing the overall symptom load and contribute to improved comfort. This supports the management of acute symptoms such as high fever, localized swelling, and pain.

“This medication is applied across domains where additional symptomatic support is needed and helps address symptom clusters that may become intense or disruptive.”

Quick Fact: Symptom Support
Support for Symptoms of Pain and Swelling
Support for maintaining functional stability
Applied for conditions involving resistant strains

Eligibility and Restrictions for Use

Who Can and Cannot Use Co-Amoxiclav?

Co-Amoxiclav (Amoxicillin and Clavulanic Acid) is a widely used antibiotic, but its suitability depends on the patient's medical history and current condition.


Who Can Typically Use Co-Amoxiclav?

Co-Amoxiclav is generally considered safe and effective for many individuals, including adults and children who require treatment for bacterial infections susceptible to this combination. This often includes common infections like respiratory tract, ear, sinus, skin, and urinary tract infections. Dosage adjustments based on kidney function and age are routine considerations by healthcare providers to ensure safe use.


Who Should NOT Use Co-Amoxiclav?

There are specific contraindications and cautions for using Co-Amoxiclav. Individuals with a known allergy or hypersensitivity to penicillin antibiotics (including amoxicillin) or clavulanic acid must not take this medication due to the risk of a severe allergic reaction (anaphylaxis).

Co-Amoxiclav is also contraindicated in patients with:

  • A history of jaundice (yellowing of the skin or eyes) or liver problems associated with previous use of Co-Amoxiclav or amoxicillin-clavulanate.
  • A history of severe kidney impairment may require dosage adjustment or avoidance, as the drug is primarily cleared by the kidneys.

Caution is advised for patients with:

  • Mononucleosis or glandular fever.
  • Certain types of leukemia.
  • Severe gastrointestinal disease.

Patients should always inform their doctor of their full medical history and current medications before starting Co-Amoxiclav.

What should I know about interactions with other medicines?

Co-Amoxiclav (amoxicillin/clavulanic acid) can interact with several other medicinal products, requiring careful monitoring. The antibiotic may prolong the effects of oral anticoagulants (e.g., Warfarin), potentially increasing the International Normalized Ratio (INR) and the risk of bleeding. Close monitoring of INR is advised during and shortly after co-administration.

The gout medication Probenecid is known to increase and prolong the concentration of amoxicillin in the bloodstream by reducing its elimination via the kidney. Conversely, the concentration of the active metabolite of Mycophenolate mofetil may be reduced, necessitating careful clinical observation.

Co-administration with Allopurinol, another gout treatment, is associated with a greater likelihood of developing allergic skin reactions. Similarly, Co-Amoxiclav may diminish the effectiveness of combined oral contraceptives by interfering with the intestinal flora responsible for estrogen reabsorption, making a backup contraceptive method necessary.

Furthermore, the antibiotic may raise the systemic levels of Methotrexate, potentially increasing the risk of toxicity. The presence of clavulanic acid can also cause non-specific binding of proteins to red cell membranes, leading to a false positive Coombs test in laboratory analyses.

Mechanism of Action

How Co-Amoxiclav Works

Inhibiting Bacterial Cell Wall Construction

This mechanism involves the Amoxicillin component, which directly targets and irreversibly binds to bacterial Penicillin-Binding Proteins (PBPs), the enzymes responsible for building the rigid structural layer of the bacterial cell wall . By blocking the final cross-linking step in wall assembly, the mechanism causes the bacteria to form a defective, fragile outer structure. This structural failure leads to the loss of osmotic stability, resulting in bacterial cell swelling, rupture (lysis), and cell death.

️ Overcoming Bacterial Defense Mechanisms

The Clavulanic Acid component acts as a necessary enhancer that addresses a common bacterial defense mechanism. It functions as a suicide inhibitor by binding to and irreversibly inactivating bacterial beta-Lactamase enzymes, which would otherwise degrade Amoxicillin. This protective, synergistic action allows the Amoxicillin component to engage its PBP targets successfully, enabling the bactericidal effect to proceed against strains producing the targeted beta-Lactamase enzyme, leading to the physiological consequence of reduced susceptible microbial populations.

Dosage and Administration Information

Co-Amoxiclav is administered via two principal routes: the oral route, utilizing standard tablets, chewable tablets, or reconstituted oral suspension; and the intravenous (IV) route, which involves a powder for injection or infusion. The method of administration is governed by the context of use, with IV forms requiring a qualified professional.

The instructions for oral formulations mandate that they must be taken at the start of a meal to mitigate potential gastrointestinal intolerance and support the absorption profile of the clavulanic acid component. This is a primary procedural constraint.

Dosing frequency is typically standardized to either twice daily (BID) or three times daily (TID), depending on the specific formulation strength used. Adult dose ranges are expressed by the amount of active components, commonly 500 mg/125 mg or 875 mg/125 mg per dose. The IV form is administered over a specific time, such as a 30- to 40-minute infusion, not as a rapid bolus.

The overall course duration generally lasts 7 to 14 days, and treatment should not extend beyond 14 days without clinical reassessment. A required dose adjustment is a necessary procedural step for patients with impaired renal function, with specific high-strength formulations being contraindicated when creatinine clearance falls below 30 mL/min. Guidance on a missed dose instructs the patient to take the dose as soon as remembered, ensuring a minimum interval of four hours passes before the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Co-Amoxiclav

Evidence for Major Systemic and Respiratory Indications

The research base for Co-Amoxiclav is primarily built on Randomized Controlled Trials (RCTs) and Systematic Reviews for treating bacterial infections. For respiratory tract conditions, such as pneumonia (LRTI) and acute sinusitis, studies were evaluated in populations of adults and children. Research examined outcomes related to systemic or functional imbalance, such as the rate of clinical success, the extent of bacteriological eradication, and changes observed in scans.

Evidence for skin, soft tissue, and bone infections is derived from Comparative Trials and Observational Studies, particularly for complicated cases like diabetic foot infections. These studies monitored outcomes reflecting daily functioning or activity level. Findings describe patterns observed in these studies, often in comparison to other established antibiotic protocols. Much of the available evidence is structured around these comparisons, which may influence how data are interpreted in studies that did not involve comparison to other active treatments.

Evidence for Acute Otitis Media and Urinary Tract Infections

Research for Acute Otitis Media (AOM) was studied for pediatric cohorts, monitoring outcomes describing episodic or acute changes like clinical cure rates and recurrence. Evidence for Urinary Tract Infections (UTI) is found within broader Clinical Efficacy Studies, with data showing patterns related to clinical success in adult populations.

Research was observed in special populations like children and adults with comorbidities such as diabetes. However, the research highlights that the results apply only to the populations studied, and data for certain groups remain insufficient. Follow-up durations were often limited, and it appears that long-term effects are not fully established, indicating that research is ongoing in many areas.

Frequently Asked Questions (FAQ)

Common questions about Co-Amoxiclav (FAQ)


Q: Can you drink alcohol while taking Co-Amoxiclav?

A: Official product information does not list a specific formal interaction between Co-Amoxiclav and alcohol. However, alcohol consumption is generally discouraged while the body is fighting an active infection. If the medicine causes common side effects like nausea or vomiting, drinking alcohol could potentially worsen these symptoms.

Q: How long does Co-Amoxiclav stay in your system after finishing the course?

A: Regulatory documents state that Co-Amoxiclav is eliminated relatively quickly from the body. The main active components, Amoxicillin and Clavulanic Acid, each have a short half-life in healthy adults. This means elimination is generally rapid, typically taking about a day for most of the medicine to be cleared.

Q: Can Co-Amoxiclav affect my sleep?

A: Sleep disturbances are not classified as a common or very common side effect in regulatory documents. However, official adverse event lists do include nervous system effects, such as dizziness and headache, which are classified as uncommon.

Q: What foods should I avoid while taking Co-Amoxiclav?

A: Official administration instructions recommend that you take Co-Amoxiclav at the start of a meal to help reduce potential gastrointestinal discomfort. No specific food groups are formally listed as being contraindicated or strictly avoided in the official labeling.

Q: Can Co-Amoxiclav interact with herbal supplements?

A: Regulatory documents list specific known interactions with certain prescription drugs, but they do not typically address every possible effect of all herbal or complementary supplements. Information on such interactions is often limited.

Q: Does Co-Amoxiclav make you sensitive to the sun?

A: Photosensitivity, or an increased sensitivity to the sun, is not classified as a common or very common side effect in regulatory documents. However, skin rashes are listed as an uncommon adverse reaction, so caution is generally advised.

Q: Is there a chewable or liquid form of Co-Amoxiclav?

A: Yes, according to official regulatory labeling, Co-Amoxiclav is available in several formulations. These include standard oral tablets, a powder that is reconstituted into an oral suspension (liquid), and chewable tablets.

Q: Can Co-Amoxiclav cause liver problems?

A: Yes, official safety information documents that severe liver problems, including hepatic dysfunction and cholestatic jaundice, are known risks. The medicine is contraindicated for individuals with a history of liver problems or jaundice linked to its previous use.

Q: Does Co-Amoxiclav affect blood sugar levels?

A: Official product information notes that high concentrations of amoxicillin in the urine can lead to false-positive results when specific methods are used for testing glucose in urine. However, regulatory documents do not indicate that the medicine directly affects blood sugar levels.

Q: Can I take probiotics while on Co-Amoxiclav?

A: Probiotics are not formally mentioned in drug interaction sections of the regulatory documents. Since this medicine can disrupt gut flora, causing common side effects like diarrhea, this has led some to consider taking probiotics.

Q: Is Co-Amoxiclav effective for UTIs (urinary tract infections)?

A: Official therapeutic indications state that Co-Amoxiclav is indicated for the treatment of urinary tract infections caused by bacteria known to be susceptible to this combination.

Q: Does Co-Amoxiclav interact with acid reflux medications?

A: Regulatory documents list several known prescription drug interactions but do not specifically address interactions with general acid reflux medications. Information on such interactions is often not detailed.

Q: Can taking Co-Amoxiclav upset my stomach long-term?

A: Gastrointestinal side effects like diarrhea and nausea are very common short-term effects that occur during treatment. While a severe risk like antibiotic-associated colitis is noted, information about long-term stomach upset after completing the course is not routinely detailed in the product information.

Q: Is Co-Amoxiclav an anti-inflammatory drug?

A: No, Co-Amoxiclav is classified as an antibacterial agent, commonly known as a penicillin-class antibiotic. It is used to resolve bacterial infections and does not have primary anti-inflammatory properties.

Q: Is there a risk of kidney issues with Co-Amoxiclav?

A: Regulatory documents mention that a dosage adjustment may be necessary for individuals with impaired kidney function. Furthermore, nervous system effects, such as convulsions, are noted to potentially occur in patients who have impaired renal function.

Q: Does Co-Amoxiclav make you feel tired or fatigued?

A: Tiredness or fatigue is not classified as a common or very common side effect according to official regulatory documents. Other nervous system effects, such as headache and dizziness, are listed as uncommon side effects.

Q: Can Co-Amoxiclav be used for a bad cold or flu?

A: Official therapeutic indications state that Co-Amoxiclav is used for the treatment of bacterial infections. It is indicated for bacterial infections and not for viral infections like the common cold or influenza (flu).

Q: Is Co-Amoxiclav safe to take during pregnancy?

A: According to official regulatory information, Co-Amoxiclav should be avoided during pregnancy unless a healthcare professional considers it essential. Studies have suggested potential risks, particularly when used for certain prophylactic reasons.

Q: How does Co-Amoxiclav prevent antibiotic resistance?

A: The Clavulanic Acid component works by inactivating specific bacterial enzymes called beta-lactamases. This shields the Amoxicillin from being broken down, allowing it to remain active and effective against certain strains that might otherwise be resistant to Amoxicillin alone.

Q: Is it possible to be allergic to just one part of Co-Amoxiclav?

A: Yes, official product information clearly states that the medicine is contraindicated, or forbidden, for individuals with a known hypersensitivity or allergy to either amoxicillin or clavulanic acid.

Q: What happens if you miss a dose of Co-Amoxiclav?

A: The regulatory guidance is that if a dose is missed, it should be taken as soon as it is remembered. The regulatory guidance includes procedural steps, such as ensuring at least four hours pass before the next scheduled dose.

Q: Does Co-Amoxiclav interact with common pain relievers like ibuprofen?

A: Regulatory documents list interactions with specific prescription drugs such as anticoagulants and Methotrexate, but they do not typically address the effects of common over-the-counter pain relievers such as ibuprofen.

Q: Is it normal to feel a bit nauseous after taking Co-Amoxiclav?

A: Yes, according to official safety information, nausea is classified as a Common side effect, meaning it is a known and expected reaction for some people taking the medication. Taking the medicine at the start of a meal can help mitigate this discomfort.

Q: Why is proper storage important for Co-Amoxiclav?

A: Official storage instructions are required to maintain the medicine's stability and ensure it remains fully effective. This is particularly important for the reconstituted liquid suspension, which must be refrigerated and discarded after a specific period to prevent loss of potency.

Q: Can I crush or break Co-Amoxiclav tablets?

A: The administration section of the product information specifies that any extended-release forms must be swallowed whole, and chewable tablets must be fully chewed. Standard tablets, in general, are intended to be swallowed whole unless explicitly directed otherwise.

Q: What should I do if my side effects from Co-Amoxiclav are mild?

A: Regulatory information lists common effects like diarrhea and nausea but primarily focuses procedural warnings on severe or life-threatening adverse reactions. For mild side effects, the focus is generally on mitigating discomfort, which may include taking the dose with food.

How should Co-Amoxiclav be stored and disposed of?

Official Storage and Disposal Requirements

Formulation Required Storage Condition Stability Constraint
Tablets / Dry Powder Controlled room temperature (20 C to 25 C), protected from light and moisture. Store in the original, tightly closed container.
Reconstituted Suspension Refrigerated (2 C to 8 C). Must not be frozen; discard after 10 days.

Co-Amoxiclav must be kept out of the reach and sight of children, as mandated by regulatory labeling. For disposal, unused or expired medicine must not be placed in household waste or flushed into wastewater. Disposal must follow local pharmaceutical waste requirements or official guidelines, such as those provided by the FDA, to ensure proper handling of unused medicinal product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Amoxiclav  found in:

A-Z Index: